Table 3.

Prevalence of chronic health conditions among overall HSCT survivors, conventional therapy survivors, and noncancer controls

Chronic health conditions (CTCAE grades ≥3)HSCT survivorsConventional therapy survivorsNoncancer controlsHSCT survivors vs conventional therapy survivorsHSCT survivors vs noncancer controls
n (%)n (%)n (%)OR (95% CI)*OR (95% CI)*
Cardiovascular 17 (15.2) 89 (8.1) 12 (5.0) 2.3 (1.3-4.1) 7.4 (2.8-19.3) 
Endocrine 29 (25.9) 422 (38.2) 91 (37.6) 0.6 (0.4-0.9) 0.8 (0.5-1.3) 
Gastrointestinal 20 (17.9) 117 (10.6) 23 (9.5) 2.1 (1.2-3.6) 3.6 (1.7-7.7) 
Neurology 9 (8.1) 83 (7.5) 15 (6.2) 1.1 (0.6-2.3) 1.6 (0.6-4.1) 
Ocular 22 (19.6) 12 (1.1) 2 (0.8) 23.2 (11.0-48.7) 47.2 (9.6-231.7) 
Pulmonary 17 (15.2) 60 (5.4) 17 (7.0) 3.5 (1.9-6.3) 2.8 (1.3-6.1) 
Reproductive 60 (53.6) 203 (18.4) 18 (7.4) 5.6 (3.7-8.4) 37.1 (16.0-86.0) 
Multiple (≥2) conditions 53 (47.3) 241 (21.8) 38 (15.7) 3.2 (2.2-4.8) 4.8 (2.9-8.0) 
Chronic health conditions (CTCAE grades ≥3)HSCT survivorsConventional therapy survivorsNoncancer controlsHSCT survivors vs conventional therapy survivorsHSCT survivors vs noncancer controls
n (%)n (%)n (%)OR (95% CI)*OR (95% CI)*
Cardiovascular 17 (15.2) 89 (8.1) 12 (5.0) 2.3 (1.3-4.1) 7.4 (2.8-19.3) 
Endocrine 29 (25.9) 422 (38.2) 91 (37.6) 0.6 (0.4-0.9) 0.8 (0.5-1.3) 
Gastrointestinal 20 (17.9) 117 (10.6) 23 (9.5) 2.1 (1.2-3.6) 3.6 (1.7-7.7) 
Neurology 9 (8.1) 83 (7.5) 15 (6.2) 1.1 (0.6-2.3) 1.6 (0.6-4.1) 
Ocular 22 (19.6) 12 (1.1) 2 (0.8) 23.2 (11.0-48.7) 47.2 (9.6-231.7) 
Pulmonary 17 (15.2) 60 (5.4) 17 (7.0) 3.5 (1.9-6.3) 2.8 (1.3-6.1) 
Reproductive 60 (53.6) 203 (18.4) 18 (7.4) 5.6 (3.7-8.4) 37.1 (16.0-86.0) 
Multiple (≥2) conditions 53 (47.3) 241 (21.8) 38 (15.7) 3.2 (2.2-4.8) 4.8 (2.9-8.0) 
*

Age/sex-adjusted ORs.

Close Modal

or Create an Account

Close Modal
Close Modal